Clinical trials: Emphysema, Pulmonary
Alpha 1-antitrypsin Deficiency (AATD)
Natural Course and Molecular Basis of Alpha 1- Antitrypsin Deficiency-associated Liver Disease.
To define the course of AATD-associated liver disease. To use the obtained samples for biomedical research which includes: 1. Search for serum-based disease biomarkers and the associated molecular pathways. 2.
- Trial name
- NCT07639996
- Testing
- Multi-omic spatial analysis
- Volunteers
- 45 people
- Sponsor
- Assiut University
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease
US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study
The purpose of this study it to evaluate the efficacy and safety of the 20 mL BLVR System in patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00515164
- Testing
- Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aeris Therapeutics
Emphysema
Analysing Peripheral Skeletal Muscle Function Before and After Endobronchial Valve Treatment
Rationale: Chronic obstructive pulmonary disease (COPD) is characterised by a high prevalence of peripheral muscle dysfunction, which can have significant clinical consequences, including decreased exercise capacity, reduced…
- Trial name
- ENDURANCE (NCT06025500)
- Testing
- 31P-Magnetic Resonance Spectroscopy (31P-MRS)
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Emphysema
Lung Volume Reduction Coil Treatment in Emphysema.
BACKGROUND: Medical therapeutic options for the treatment of emphysema remain limited. Lung volume reduction surgery is infrequently used because of its high morbi-mortality.
- Trial name
- STICREVOLENS (NCT01822795)
- Testing
- Lung volume reduction coïl treatment, Regular medical treatment
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- CHU de Reims
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in…
- Trial name
- NCT02951312
- Testing
- Glycopyrrolate Inhalation Solution 25mg, Glycopyrrolate Inhalation Solution 75mg, Glycopyrrolate Inhalation Solution 200mg
- Volunteers
- 12 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease (COPD), Emphysema
Evaluating Genes in Sputum to Measure Drug Response in COPD
The purpose of this research study is to determine whether analysis of genes in sputum is a useful noninvasive technique for measuring response to drugs in patients with COPD.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Trial name
- NCT00233051
- Testing
- Salmeterol or Salmeterol/Fluticasone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Jewish Health
Chronic Obstructive Pulmonary Disease (COPD)
Examining Vascular Outcomes in COPD Inpatients (AIM 1) Examining Early Rehabilitation on Discharged COPD Patients (AIM 2)
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease primarily caused by smoking. COPD creates a tremendous burden to the healthcare system, as disease exacerbations result in frequent, prolonged…
- Trial name
- NCT01949727
- Testing
- AIM 2: Pulmonary Rehabilitation
- Where
- Canada
- Volunteers
- 111 people
- Sponsor
- University of Alberta
Heterogeneous Emphysema
Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)
The purpose of this study is to evaluate the safety and feasibility of the Chartis System in measuring air flow and pressures in isolated lung compartments in emphysema patients prior to endobronchial lung volume reduction (ELVR).
- Trial name
- NCT00684892
- Testing
- Chartis System
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Pulmonx Corporation
Emphysema, Alpha 1-proteinase Inhibitor Deficiency
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® intravenous (i.v).
- Trial name
- NCT00670007
- Testing
- Alpha1- proteinase inhibitor [human]
- Where
- 21 sites in Australia, Canada and 9 more
- Volunteers
- 140 people
- Sponsor
- CSL Behring
Pulmonary Emphysema
Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205907
- Testing
- BLVR Hydrogel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Aeris Therapeutics
Emphysema or COPD, Aneurysm
The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation
Background: Elastin is a unique protein providing elasticity, resilience and deformability to dynamic tissues, such as lungs and vasculature. Elastin fibers are characterized by their high affinity for calcium.
- Conditions
- Emphysema or COPD, Aneurysm, Cystic Fibrosis, Alpha 1-Antitrypsin Deficiency
- Trial name
- NCT03285100
- Testing
- Venipuncture
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Canisius-Wilhelmina Hospital
Alpha-1 Antitrypsin Deficiency
A Phase 1, First-in-human Study of VX-668
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.
- Trial name
- NCT05727800
- Testing
- VX-668
- Where
- 5 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
COPD, Emphysema
Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD
Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause for morbidity and mortality. Despite the high clinical significance of sarcopenia in COPD, the diagnosis remains elusive because…
- Conditions
- COPD, Emphysema, Sarcopenia
- Trial name
- NCT07059637
- Testing
- Multidisciplinary clinic evaluation, COPD standard of care
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Cleveland Clinic
Chronic Obstructive Pulmonary Disease, Emphysema
Macrophages in Smokers' Lung
Cigarette smoking causes an increase in inflammation in the lungs. In about 20% of smokers this inflammation leads to damage in lungs including making holes in the lung tissue.
- Conditions
- Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis
- Trial name
- NCT00298402
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Imperial College London
Alpha 1-Antitrypsin Deficiency
Study of ARO-AAT in Normal Adult Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-AAT in healthy adult volunteers.
- Trial name
- NCT03362242
- Testing
- ARO-AAT Injection, Sterile Normal Saline (0.9% NaCl)
- Where
- New Zealand
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Obstructive Pulmonary Disease
An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease
This study is investigating the possible mechanisms of action of an inhaled treatment (Seretide), currently used worldwide in millions of patients with COPD (Chronic Obstructive Pulmonary Disease) and how it improves the symptoms…
- Trial name
- IMAS (NCT00974805)
- Testing
- Seretide 500 Accuhaler
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Southampton
COPD, Emphysema
Bronchitis and Emphysema Advice and Training to Reduce Hospitalization
EXECUTIVE SUMMARY: Purpose: To evaluate the efficacy and cost-effectiveness of a novel intervention incorporating self-management education, an action plan, and case-management to decrease the risk of hospitalizations due to…
- Trial name
- BREATH (NCT00395083)
- Testing
- COPD Self-management Education
- Where
- 22 sites in United States
- Volunteers
- 426 people
- Sponsor
- US Department of Veterans Affairs
Pulmonary Disease, Chronic Obstructive
28-day Repeat Dose Study of GSK573719
The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD
- Trial name
- NCT01030965
- Testing
- GSK573719 125mcg, GSK573719 250mcg, GSK573719 500mcg
- Where
- 20 sites in United States, Estonia and 2 more
- Volunteers
- 285 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD), Smoking
The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease
Cigarette smoking is the major risk factor for chronic obstructive pulmonary disease (COPD, commonly known as chronic bronchitis and emphysema).
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Chronic Bronchitis
- Trial name
- NCT00974064
- Where
- United States
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Interstitial Lung Disease, COPD
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as…
- Conditions
- Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- GUARDIANLUNG (NCT04930289)
- Testing
- LungGuard, BAROGuard
- Where
- 15 sites in United States, Belgium
- Volunteers
- 3,500 people
- Sponsor
- Paragonix Technologies